{
    "root": "3487033c-7c62-4034-8718-73a7c49b26a0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "DICLOFENAC SODIUM"
    },
    "value": "20250509",
    "ingredients": [
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C YELLOW NO. 6 ALUMINUM LAKE",
            "code": "GYP6Z2JR6Q"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "DIMETHICONE, UNSPECIFIED",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "HYPROMELLOSE 2910 (50 MPA.S)",
            "code": "1IVH67816N"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "FD&C RED NO. 40 ALUMINUM LAKE",
            "code": "6T47AS764T"
        }
    ],
    "indications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  \n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                  \n                     for relief of the signs and symptoms of osteoarthritis\n                     for relief of the signs and symptoms of rheumatoid arthritis\n                     for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  \n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient’s needs.\n                  \n                  For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  \n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day.).\n                  \n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25 mg dose at bedtime if necessary.\n                  \n                  Different formulations of diclofenac [(diclofenac sodium enteric-coated tablets); diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets)] are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions": "Diclofenac Sodium Delayed-Release Tablets, USP are available containing 50 mg or 75 mg of diclofenac sodium, USP.\n                  \n                  The 50 mg tablets are light brown, round, biconvex, enteric coated tablet imprinted “D50” in black ink on one side and plain on other side. They are available as follows:\n                  \n                  Bottles of 60                           NDC 59651-842-60\n                  Bottles of 100                         NDC 59651-842-01\n                  Bottles of 1,000                      NDC 59651-842-99\n                  \n                  The 75 mg tablets are pale pink, round, biconvex, enteric coated tablet imprinted “D75” in black ink on one side and plain on other side. They are available as follows: \n                  Bottles of 60                           NDC 59651-843-60\n                  Bottles of 100                         NDC 59651-843-01\n                  Bottles of 500                         NDC 59651-843-05\n                  Bottles of 1,000                      NDC 59651-843-99\n                  \n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] \n                     \n                  \n                  \n                     \n                  \n                  \n                     Protect from moisture.\n                  \n                  Dispense in a tight, light-resistant container as described in the USP using a child-resistant closure.\n                     \n                         Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides.\n                        \n                     \n                      Distributed by:\n                     Aurobindo Pharma USA, Inc.\n                     279 Princeton-Hightstown Road East Windsor, NJ 08520\n                      Manufactured by:\n                     Aurobindo Pharma Limited\n                     Hyderabad-500 032, India\n                      Revised: 01/2025",
    "adverseReactions": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients: \n                  \n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see WARNINGS; Anaphylactic Reactions, Serious Skin Reactions). \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see WARNINGS; Anaphylactic Reaction, Exacerbation of Asthma Related to Aspirin Sensitivity). \n                     In the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS;  Cardiovascular Thrombotic Events)."
}